Compile Data Set for Download or QSAR
Report error Found 130 Enz. Inhib. hit(s) with all data for entry = 12483
TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699247(US20240327430, Example 87 | US12145945, Example 87)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699248(US20240327430, Example 88 | US12145945, Example 88)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699245(US20240327430, Example 85 | US12145945, Example 85)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699246(US20240327430, Example 86 | US12145945, Example 86)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699243(US20240327430, Example 83 | US12145945, Example 83)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699244(US20240327430, Example 84 | US12145945, Example 84)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699241(US20240327430, Example 81 | US12145945, Example 81)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699242(US20240327430, Example 82 | US12145945, Example 82)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM705457(2'-chloro-N-(5-{[(2R)-2- hydroxypropyl]amino}- [1,...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM705458(2'-chloro-N-(5-{[(2S)-2- hydroxypropyl]amino}- [1,...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM705455(2'-fluoro-5'-methoxy-6-methyl-N-[5-(morpholin-4-yl...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699254(US20240327430, Example 94 | US12145945, Example 94)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699251(US20240327430, Example 91 | US12145945, Example 91)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699252(US20240327430, Example 92 | US12145945, Example 92)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699249(US20240327430, Example 89 | US12145945, Example 89)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699250(US20240327430, Example 90 | US12145945, Example 90)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699231(US20240327430, Example 71 | US12145945, Example 71)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699232(US20240327430, Example 72 | US12145945, Example 72)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699229(US20240327430, Example 69 | US12145945, Example 69)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699230(US20240327430, Example 70 | US12145945, Example 70)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699227(US20240327430, Example 67 | US12145945, Example 67)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM705430(2'-chloro-N-[6-(4-hydroxypiperidin-1-yl)- [1,3]thi...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699225(US20240327430, Example 65 | US12145945, Example 65)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699226(US20240327430, Example 66 | US12145945, Example 66)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699239(US20240327430, Example 79 | US12145945, Example 79)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699240(US20240327430, Example 80 | US12145945, Example 80)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699237(US20240327430, Example 77 | US12145945, Example 77)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699238(US20240327430, Example 78 | US12145945, Example 78)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699235(US20240327430, Example 75 | US12145945, Example 75)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699236(US20240327430, Example 76 | US12145945, Example 76)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699233(US20240327430, Example 73 | US12145945, Example 73)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699234(US20240327430, Example 74 | US12145945, Example 74)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699279(5-[(2-{2'-chloro-5'-methoxy-6-methyl- [4,4'-bipyri...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM705482(2'-chloro-5'-methoxy-6-methyl-N-{5- [(2H-1,2,3,4-t...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM705479(2'-chloro-5'-methoxy-6-methyl-N-[5-(2- oxopiperidi...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699278(5-[(2-{2'-chloro-5'-methoxy-6-methyl- [4,4'-bipyri...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699275(6-[(dimethylcarbamoyl)methyl]-5'- methoxy-N- {[1,3...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699276(N-[5-(4-hydroxypiperidin-1-yl)- [1,3]thiazolo[5,4-...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699287(2'-chloro-5'-methoxy-6-methyl-N-[6- (morpholin-3-y...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699288(2'-chloro-5'-methoxy-N-[6-(3- methoxyazetidin-1-yl...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699285(2'-chloro-N-[7-(cyanomethoxy)- [1,3]thiazolo[5,4-d...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699286(N-[7-(carbamoylmethoxy)- [1,3]thiazolo[5,4-d]pyrim...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699282(2-[(2-{2'-chloro-5'-methoxy-6-methyl- [4,4'-bipyri...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699228(US20240327430, Example 68 | US12145945, Example 12...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699281(2'-chloro-N-(5-hydroxy-1,3- benzothiazol-2-yl)-5'-...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699283(2'-chloro-N-[5-(2-hydroxyethoxy)-1,3- benzothiazol...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699263(2'-chloro-N-{5-[(dimethylcarbamoyl) difluoromethox...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699264(2'-chloro-5'-methoxy-6-methyl-N-[5- (methylcarbamo...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699261(2'-chloro-N-{5- [difluoro(methylcarbamoyl) Methoxy...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699262(N-(5-bromo-1,3-benzothiazol- 2-yl)-2'-chloro-5'-me...)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Polθ protein (P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/8/2025
Entry Details
US Patent

Displayed 1 to 50 (of 130 total ) | Next | Last >>
Jump to: